| Autor: |
Fleming D; Division of Clinical Microbiology, Mayo Clinic, Rochester, MN., Bozyel I; The Gene and Linda Voiland School of Chemical Engineering and Bioengineering, Washington State University, Pullman, WA., Koscianski CA; Division of Clinical Microbiology, Mayo Clinic, Rochester, MN., Ozdemir D; The Gene and Linda Voiland School of Chemical Engineering and Bioengineering, Washington State University, Pullman, WA., Karau MJ; Division of Clinical Microbiology, Mayo Clinic, Rochester, MN., Cuello L; Division of Clinical Microbiology, Mayo Clinic, Rochester, MN., Anoy MMI; The Gene and Linda Voiland School of Chemical Engineering and Bioengineering, Washington State University, Pullman, WA., Gelston S; The Gene and Linda Voiland School of Chemical Engineering and Bioengineering, Washington State University, Pullman, WA., Schuetz AN; Division of Clinical Microbiology, Mayo Clinic, Rochester, MN., Greenwood-Quaintance KE; Division of Clinical Microbiology, Mayo Clinic, Rochester, MN., Mandrekar JN; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN., Beyenal H; The Gene and Linda Voiland School of Chemical Engineering and Bioengineering, Washington State University, Pullman, WA., Patel R; Division of Clinical Microbiology, Mayo Clinic, Rochester, MN.; Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, MN. |
| Abstrakt: |
Wound infections, exacerbated by the prevalence of antibiotic-resistant bacterial pathogens, necessitate innovative antimicrobial approaches. Polymicrobial infections, often involving Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA), present formidable challenges due to biofilm formation and antibiotic resistance. Hypochlorous acid (HOCl), a potent antimicrobial agent produced naturally by the immune system, holds promise as an alternative therapy. An electrochemical bandage (e-bandage) that generates HOCl in situ was evaluated for treatment of murine wound biofilm infections containing both MRSA and P. aeruginosa with "difficult-to-treat" resistance. Previously, the HOCl-producing e-bandage was shown to reduce wound biofilms containing P. aeruginosa alone. Compared to non-polarized e-bandage (no HOCl production) and Tegaderm only controls, the polarized e-bandages reduced bacterial loads in wounds infected with MRSA plus P. aeruginosa (MRSA: vs Tegaderm only - 1.4 log 10 CFU/g, p = 0.0015, vs. non-polarized - 1.1 log 10 CFU/g, p = 0.026. P. aeruginosa : vs Tegaderm only - 1.6 log 10 CFU/g, p = 0.0015, vs non-polarized - 1.6 log 10 CFU/g, p = 0.0032), and MRSA alone (vs Tegaderm only - 1.3 log 10 CFU/g, p = 0.0048, vs. non-polarized - 1.1 log 10 CFU/g, p = 0.0048), without compromising wound healing or causing tissue toxicity. Addition of systemic antibiotics did not enhance the antimicrobial efficacy of e-bandages, highlighting their potential as standalone therapies. This study provides additional evidence for the HOCl-producing e-bandage as a novel antimicrobial strategy for managing wound infections, including in the context of antibiotic resistance and polymicrobial infections. |
